Previous Page  9 / 25 Next Page
Information
Show Menu
Previous Page 9 / 25 Next Page
Page Background

Volume 4, Issue 6(Suppl)

J Infect Dis Ther

ISSN: 2332-0877 JIDT, an open access journal

Page 55

Notes:

Influenza 2016

September 12-13, 2016

conferenceseries

.com

Influenza

September 12-13, 2016 Berlin, Germany

2

nd

International Conference on

Quantification of the haemagglutinin in monovalent influenza vaccines by a latex agglutination assay

(LAA) as an alternative to the single radial immunodiffusion (SRID) assay

Sophie Buffin

Sanofi Pasteur, France

T

o formulate inactivated influenza vaccines, the concentration of haemagglutinin (HA) must be accurately determined. The

standard test currently used to measure HA in influenza vaccines is the single radial immunodiffusion (SRID) assay. The SRID

assay is a cumbersome technique presenting a number of drawbacks such as low sensitivity and interference by some adjuvants. We

developed a very simple, sensitive and rapid alternative HA assay using latex agglutination. The LAA uses the Spherotest® technology,

which is based on the agglutination of HA-specific immunoglobulin-coated latex beads, which bind to the HA. The amount of HA

in a sample can then be calculated from the level of bead agglutination by a simple absorbance measurement. A standard curve is

generated using serially diluted HA reference protein. The results show that for monovalent A/H5N1 and A/H1N1 vaccines, the

LAA demonstrated equivalent linearity, accuracy and precision as compared to the SRID assay. Moreover, unlike the SRID assay,

LAA enables HA quantification in AlOOH-adjuvanted vaccines and in emulsion-based adjuvanted vaccines without interference.

In addition, LAA was found to be more simple, rapid and sensitive than SRID. In conclusion, LAA may be useful to rapidly and

accurately quantify the influenza HA protein in monovalent vaccines, especially in those formulated with low amounts of HA in the

presence of an adjuvant.

Biography

Sophie Buffin joined the Research department of Sanofi Pasteur in 2005 with a Master’s degree. She is currently a Ph.D. student at the University of Lyon.

sophie.buffin@sanofipasteur.com

Sophie Buffin, J Infect Dis Ther 2016, 4:6(Suppl)

http://dx.doi.org/10.4172/2332-0877.C1.015